LAX.SH
DR. REDDY S LABORATORIES·PHARMACEUTICALS 66.37·Pharmaceuticals & Biotechnology Companies
Price
1,239
-0.45%52W Range
Market Cap
₹1,03,416.89 Cr
Traded: ₹345.67 Cr (0.33%) 0.0x
Free Float: ₹9,669.48 Cr (3.57% of FF traded)
Volume · 60D trend
28.05 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +8.0% | +12.0% | +11.0% | -- | -1.0% | Decelerating |
| ROE | +15.0% | +16.0% | +16.0% | -- | -- | Stable |
| Return | +5.0% | +2.0% | +4.0% | -5.0% | -- | Stable |
| Profit | +7.0% | +15.0% | -4.0% | -- | -43.0% | Decelerating |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8,100 | 7,546 | 8,753 | 8,828 | 8,572 | 8,528 | 8,381 | 8,038 | 7,696 | 7,114 | 7,237 | 6,903 | 6,758 | 6,315 | 6,790 |
| Expenses | 7,240 | 7,164 | 6,866 | 6,818 | 6,398 | 6,530 | 6,108 | 5,962 | 5,566 | 5,283 | 5,214 | 4,894 | 4,696 | 4,781 | 4,851 |
| Operating Profit | 860 | 382 | 1,888 | 2,010 | 2,174 | 1,998 | 2,273 | 2,076 | 2,130 | 1,831 | 2,023 | 2,008 | 2,062 | 1,534 | 1,939 |
| Other Income | 356 | 480 | 271 | 330 | 290 | 528 | 154 | 314 | 193 | 201 | 219 | 319 | 178 | 146 | 65 |
| Interest | 126 | 106 | 94 | 91 | 83 | 66 | 82 | 76 | 60 | 59 | 39 | 35 | 37 | 35 | 42 |
| Depreciation | 537 | 557 | 521 | 505 | 476 | 455 | 471 | 397 | 381 | 368 | 374 | 376 | 353 | 316 | 324 |
| Profit Before Tax | 553 | 200 | 1,543 | 1,745 | 1,905 | 2,005 | 1,874 | 1,917 | 1,883 | 1,605 | 1,829 | 1,917 | 1,850 | 1,329 | 1,638 |
| Tax % | 21.0% | -11.0% | 23.0% | 23.0% | 26.0% | 21.0% | 25.0% | 30.0% | 26.0% | 18.0% | 24.0% | 23.0% | 24.0% | 28.0% | 24.0% |
| Net Profit | 436 | 221 | 1,190 | 1,337 | 1,410 | 1,587 | 1,404 | 1,342 | 1,392 | 1,310 | 1,381 | 1,482 | 1,405 | 960 | 1,244 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 5.3 | 2.6 | 14.5 | 16.1 | 17.0 | 19.1 | 16.9 | 15.1 | 16.7 | 15.7 | 16.6 | 17.8 | 16.9 | 11.5 | 14.9 |
| Sales Growth (YoY) | -5.5% | -11.5% | 4.4% | 9.8% | 11.4% | 19.9% | 15.8% | 16.4% | 13.9% | 12.7% | 6.6% | -- | -- | -- | -- |
| Sales Growth (QoQ) | 7.3% | -13.8% | -0.8% | 3.0% | 0.5% | 1.8% | 4.3% | 4.4% | 8.2% | -1.7% | 4.8% | 2.1% | 7.0% | -7.0% | -- |
| OP Growth (YoY) | -60.4% | -80.9% | -16.9% | -3.2% | 2.1% | 9.1% | 12.4% | 3.4% | 3.3% | 19.4% | 4.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | 125.1% | -79.8% | -6.1% | -7.5% | 8.8% | -12.1% | 9.5% | -2.5% | 16.3% | -9.5% | 0.7% | -2.6% | 34.4% | -20.9% | -- |
| Profit Growth (YoY) | -- | -86.0% | -14.0% | 7.0% | 2.0% | 22.0% | 2.0% | -15.0% | -1.0% | 36.0% | 11.0% | 33.0% | 18.0% | 890.0% | 75.0% |
| EPS Growth (YoY) | -68.7% | -86.1% | -14.4% | 7.2% | 1.8% | 21.6% | 2.3% | -15.3% | -1.1% | 36.2% | 10.8% | -- | -- | -- | -- |
| EPS Growth (QoQ) | 100.8% | -81.7% | -10.2% | -5.0% | -11.0% | 12.7% | 12.6% | -9.8% | 6.3% | -5.2% | -6.8% | 5.3% | 46.3% | -22.8% | -- |
| OP Margin | 10.6% | 5.1% | 21.6% | 22.8% | 25.4% | 23.4% | 27.1% | 25.8% | 27.7% | 25.7% | 27.9% | 29.1% | 30.5% | 24.3% | 28.6% |
| Net Margin | 5.4% | 2.9% | 13.6% | 15.1% | 16.4% | 18.6% | 16.8% | 16.7% | 18.1% | 18.4% | 19.1% | 21.5% | 20.8% | 15.2% | 18.3% |
| Material Cost % | -- | 42.6% | 35.4% | 35.4% | 32.8% | 33.4% | 30.8% | 29.4% | 28.4% | 29.4% | 30.1% | 29.0% | 28.7% | 30.1% | 29.5% |
| Employee Cost % | -- | 19.2% | 18.1% | 16.4% | 17.5% | 16.4% | 16.3% | 17.4% | 18.4% | 18.0% | 17.6% | 18.6% | 17.6% | 20.2% | 17.3% |
| P/S | 3.11 | 2.99 | 3.08 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 32.09 | 23.99 | 19.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 2.73 | 2.66 | 2.97 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Intimation of Earnings call
Certificate under Regulation 74(5) of SEBI (Depositories & Participants) Regulations, 2018
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Closure of Trading window
Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/10/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Intimation of analyst meet
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
The Exchange has sought clarification from Dr Reddys Laboratories Ltd on September 17, 2026, with reference to news appeared in https://pharma.economictimes.indiatimes.com/ dated September ....
Copies of newspaper publication
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Allotment of Employee Stock options
Intimation of Analyst meet
Allotment of Employee Stock options
Copies of newspaper publication
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Change in Senior Management Personnel
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2105
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2105
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Scrutinizer''s Report
Outcome of 42nd Annual General Meeting
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015
Copy of newspaper publication
Intimation of Earnings call recordings
Outcome of Board Meeting held on July 22, 2026
Copy of Investor Presentation
Grant of Employee Stock Options
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Unaudited Financial results for the quarter ended June 30, 2026
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Conference Call Transcript
Intimation of Earnings call
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Certificate under Reg 74(5) of SEBI (Depositories and Participants), Regulations, 2018
Please find enclosed copy of Newspaper Publication
Please find enclosed copy of Newspaper Publication
Please find enclosed Notice of the 42nd Annual General Meeting of the Company.
Please find enclosed Integrated Annual Report FY 2025-26
Please find enclosed Business Responsibility and Sustainability Report FY 2026
Please find enclosed letter to shareholder in relation to Integrated Annual Report of the Company for FY 2025-26
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2026 ,inter alia, to consider and approve the Un-audited Standalone ....
Intimation regarding Closure of Trading window
Annual Reports
15Credit Ratings
6Concalls
30Jan 2026
31 Jan 2026Jan 2026
31 Jan 2026Oct 2025
31 Oct 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Jan 2025
31 Jan 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Jul 2024
31 Jul 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Jul 2023
31 Jul 2023May 2023
31 May 2023Jan 2023
31 Jan 2023Nov 2022
30 Nov 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021May 2021
31 May 2021May 2020
31 May 2020Jan 2020
31 Jan 2020Oct 2019
31 Oct 2019Jul 2019
31 Jul 2019Apr 2017
30 Apr 2017Oct 2016
31 Oct 2016Jul 2016
31 Jul 2016Apr 2016
30 Apr 2016Nov 2015
30 Nov 2015Held by ETFs
68 ETFs hold drreddy · sorted by weight
Held by Mutual Funds
126 schemes hold drreddy · sorted by weight